Co-targeting NRF2 potentially enhances the in vitro anticancer effects of paclitaxel in gastric cancer cells
Our findings suggest that paclitaxel combined with siRNA-mediated silencing of NRF2 might represent a promising therapeutic strategy for GC, however further translational and clinical research are warranted.
Authors
- Behzad Baradaran (ORCID: https://orcid.org/0000-0002-8642-6795)
- Shima Hasani
- Sahar Safaei (ORCID: https://orcid.org/0000-0001-7181-9396)
- Mohammad Khalaj‐Kondori (ORCID: https://orcid.org/0000-0001-9231-889X)
- Mohammad Amini (ORCID: https://orcid.org/0000-0001-7543-9577)
- Mohadeseh Maghsoudi
- Negin Riazi-Tabrizi
Institutions
- Tabriz University of Medical Sciences (IR)
- University of Tabriz (IR)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1007/s12672-024-01312-6
- Citations
- 4
- Primary Topic
- Genomics, phytochemicals, and oxidative stress
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Tabriz University of Medical Sciences
- University of Tabriz